Verifying Death Reports in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

Victor Serebruany, MD, PhD,1* Jean-Francois Tanguay, MD,2 Mario Alberto Benavides, MD,3 Hector Cabrera-Fuentes, MD, PhD,4 Wolfgang Eisert, MD, PhD,5 Moo Hyun Kim, MD,6 Junghan Yoon, MD,7 Cheol-Whan Lee, MD,8 Kiyuk Jang, MD,9 James Swan, MD,10 and Thomas Marciniak, MD,11 For the Clinical Trials Outcomes Verification Task Force

Background: Excess vascular deaths in the PLATO trial comparing ticagrelor to clopidogrel have been repeatedly challenged by the Food and Drug Administration (FDA) reviewers and academia. Based on the Freedom of Information Act, BuzzFeed won a court order and shared with us the complete list of reported deaths for the ticagrelor FDA New Drug Application (NDA) 22-433. This dataset was matched against local patient-level records from PLATO sites monitored by the sponsor.

Study Question: Whether FDA death data in the PLATO trial matched the local site records.

Study Design: The NDA spreadsheet contains 938 precisely detailed PLATO deaths. We obtained and validated local evidence for 52 deaths among 861 PLATO patients from 14 enrolling sites in 8 countries and matched those with the official NDA dataset submitted to the FDA.

Measures and Outcomes: Existence, precise time, and primary cause of deaths in PLATO.

Results: Discrepant to the NDA document, sites confirmed2 extra unreported deaths (Poland and Korea) and failed to confirm 4 deaths (Malaysia). Of the remaining 46 deaths, dates were reported correctly for 42 patients, earlier (2 clopidogrel), or later (2 ticagrelor) than the actual occurrence of death. In 12 clopidogrel patients, cause of death was changed to “vascular,” whereas 6 NDA ticagrelor “nonvascular” or “unknown”
deaths were site-reported as of “vascular” origin. Sudden death was incorrectly reported in 4 clopidogrel patients, but omitted in 4 ticagrelor patients directly affecting the primary efficacy PLATO endpoint.

Conclusions: Many deaths were inaccurately reported in PLATO favoring ticagrelor. The full extent of mortality misreporting is currently unclear, while especially worrisome is a mismatch in identifying primary death cause. Because all PLATO events are kept in the cloud electronic Medidata Rave capture system, securing the database content, examining the dataset changes or/and repeated entries, identifying potential interference origin, and assessing full magnitude of the problem are warranted.

Keywords: clinical trial, ticagrelor, clopidogrel, death, mortality

INTRODUCTION

Despite the Food and Drug Administration (FDA’s) controversial decision to approve ticagrelor in 2011,1 the drug’s use has been expanding around the globe.2 Currently, ticagrelor holds a superiority recommendation over clopidogrel for acute coronary syndromes in European,3 Canadian,4 and American5 guidelines based mostly on the results of the PLATO trial.6 However, the advantages of ticagrelor over clopidogrel in PLATO were inconsistent and exhibited “geographical” differences,7 the latter depending upon whether or not the sponsor had been involved in site monitoring in certain countries.8,9 The second uncertainty following PLATO occurred after the delayed PHILO trial results publication became available.10 That study was designed to gain regulatory approval of ticagrelor in Japan, matching precisely with the PLATO design. However, there were numerically more cardiovascular and all-cause deaths with ticagrelor in PHILO, similar to the independently monitored PLATO US results, and challenging the ticagrelor mortality benefit reported in the sponsor-controlled PLATO cohort.11,12 Lack of ticagrelor mortality benefit observed in PHILO was consistent with other trials justifying independent verification of deaths in PLATO.12 Recently, data from the large, uniform, US government-run international repository suggested a consistent disproportional excess of mortality associated with ticagrelor when compared with clopidogrel and especially with prasugrel.2 Finally, consistent lack of mortality benefit confirmation in all other ticagrelor trials supports the verification of PLATO deaths by the Task Force (Table 1). The above discrepancies led us to seek verification of PLATO deaths despite a decade having passed.

METHODS

Lately, based on the US Freedom of Information Act, BuzzFeed news filed a legal complaint in a US federal court (Figure 1), won an expedited order, and shared with us the complete PLATO death list submitted by the ticagrelor New Drug Application (NDA) 22–433 sponsor. We matched the NDA dataset with the medical records or/and vital registries provided by several PLATO sites monitored by the sponsor. The NDA spreadsheet contains 938 PLATO deaths with trial identification numbers, country, enrolling site, patient age, gender, treatment assignments, discontinuations, outcome codes, dates, and precise causes of trial entry and exit. We obtained data for 861 PLATO patients including 52 deaths from 14 enrolling sites in 8 countries and matched those with the NDA dataset.

RESULTS

Overall, we were able to obtain patient-level local data from 14 PLATO sites in 8 countries (Canada, Hungary, Israel, Malaysia, Mexico, Norway, Poland, and South Korea). Principal investigators from Israel and Malaysia cooperated, but were not able to retrieve original trial clinical records. The Malaysian PLATO team, however, provided detailed personal recollections and confirmed affidavits from principal investigator and research coordinator regarding site deaths. We received death details from a high recruiting Polish site including clinical notes and Powszechny Elektroniczny System Ewidencji Ludności national registry transcripts.

Most PLATO deaths match precisely between the original site records and the NDA-reported events. Indeed, most causes and timings of deaths were reported and transferred correctly. But not all reports match. First, there was a discrepancy between the published PLATO death counts5 and the numbers of fatalities reported by NDA 22–433. These differences are outlined in Table 2. It is actually positive that the NDA dataset reported all deaths rather than just those used for intend to treat analyses. The reduction in death counts from the NDA to the published data5 seems reasonable, although
slightly disproportional favoring ticagrelor, and may represent a legitimate attempt to remove extra fatalities because of the complicated nature of the trial design. For example, the analysis period in PLATO was strictly limited to 12 months. We observed several cases for which the patient was still receiving a study drug within the active trial frame and experienced an adverse outcome which was properly not counted. Also, unusual but not incorrect was the decision to include the bleeding deaths not related to trauma as a component of the primary endpoint.

The comparison of NDA-reported ticagrelor versus clopidogrel deaths in different countries is shown in Table 3. The geographic distribution of death rates was remarkably inconsistent in PLATO. Even within Europe, deaths rates varied between 1.95% in Finland to 4.93% in Germany. Overall, we analyzed data for 52 PLATO deaths from 14 enrolling sites in 8 countries and matched those with the NDA dataset. Discrepancies between local site records and what has been reported in the NDA are outlined below (Tables 4–6).

Table 1. Justification for independent verification of deaths in PLATO.

| PLATO fact                                                                 | Comment                                                                                                                                 |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
| Discrepancy in mortality between Phase II and Phase III trials           | In contrast to PLATO, earlier studies (Dose confirmation Study assessing anti-Platelet Effects of AZD6140 vs clopidogrel in non-STSegment Elevation myocardial infarction and Dose confirmation Study assessing anti-Platelet Effects of AZD6140 vs clopidogrel in non-STSegment Elevation myocardial infarction-2) run by the Thrombolysis in Myocardial Infarction group exhibit more deaths with ticagrelor. |
| Extraordinary high death rate after clopidogrel therapy                 | All-cause mortality (5.9%) was extremely high. This happened despite 46% of patients were pretreated with clopidogrel, excessive incomplete follow-up (14.7%), and PLATO’s relatively short duration (median 10.5 mo). |
| Average death rates and inversed outcomes in the USA                     | The US mortality was 3.22% for clopidogrel, same as in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel (3.2%), but 3.84% in US for ticagrelor. |
| Delayed timing of ticagrelor mortality “benefit”                         | Lack of early, but massive delayed (after 2–3 mo) ticagrelor mortality prevention unseen for any antiplatelet drug in any Acute Coronary Syndrome (ACS) trial. |
| High proportion of vascular deaths                                       | Excess proportion of deaths from vascular causes (89%) in clopidogrel arm.                                                                 |
| Mismatch between myocardial infarction (MI) and death rates             | The corresponding MI rate in clopidogrel arm (6.9%) is realistic, but contradicts unreasonably high (5.1%) risk of vascular deaths. |
| Prevention of unusual causes of deaths by any antiplatelet agent         | Reduction of sudden death (n = 17), heart failure (n = 11), arrhythmia (n = 8), and sepsis (n = 16) fatalities by ticagrelor |
| Late change of trial monitoring control                                  | Thrombolysis in Myocardial Infarction group has been preplanned to run PLATO, but instead, ticagrelor sponsor did that. |
| East European “paradox” in outcomes                                     | Poland (0.69; 0.53–0.90) and Hungary (0.59; 0.40–0.86) yielded the narrowest hazard ratio for outcomes among all countries. These 2 countries combined account for 21% of enrolled patients, but yielded 46% of events favoring ticagrelor. |
| Description of deceased clopidogrel patient who later developed nonfatal bleeding in the NDA 22–433 review | May represent unintentional error or broken uncovered pattern of fraud |
| Similarity with rosvastatin in Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin | Similar dissociation between average MI rates and high mortality in control arms for both trials with astronomical names. |
DISCUSSION

Missing or incorrect data are concerning for validation of clinical trials. The major finding of this report is that actual existence, precise dates, and proper causes of some deaths in PLATO were mismatched between what was sent by the local sites and what was received by the FDA. Several clopidogrel deaths were reported earlier than actual, whereas their causes were switched from “nonvascular” or “unknown” to “vascular.”

Table 2. Deaths in PLATO by issued source.

| Source          | Ticagrelor (n) | Clopidogrel (n) | Total (n) |
|-----------------|---------------|----------------|-----------|
| PLATO published | 399           | 506            | 905       |
| NDA reported    | 420           | 518            | 938       |
contrast, few ticagrelor deaths were reported later and some vascular deaths were incorrectly entered in the NDA list as “non-vascular” or “unknown.” Importantly, principal investigators, attending physicians, interventional cardiologists, research coordinators, study nurses, and local sponsor monitors should not be held responsible for data interference because they consistently and sincerely reported true validated events or committed few unintentional errors with the Medidata Rave electronic data capture system entries, which was universally used in PLATO. As expected, there were several unintentional mistakes such as wrong patient name, gender, or erroneous year of enrollment. However, we found no evidence whatsoever that sites per se deliberately reported incorrect mortality data. Without detailed review of local site records, but based exclusively on national vital registries, these PLATO misreporting issues would not have been revealed since all misreported patients were actually deceased. Sooner or later, from different primary cause, but dead making any proper adjudication attempt impossible to achieve considering lack of paper records.

Regarding the discrepancy in total PLATO deaths, the dataset “cleaning” resulted in more removed ticagrelor (n = 21) than clopidogrel (n = 12) deaths. In fact, all deaths within the trial period should be counted although PLATO excluded deaths after “withdrawal of consent”. Importantly, withdrawal of consent or volunteer discontinuations for ticagrelor patients seems to have been quite liberal.1,9 The geographical differences in death rates reported in PLATO are wide, although the current dataset is not sufficient to make any definite conclusions. Indeed, within the same continent guided by universal recommendations, Europe yielded very different deaths numbers starting from low rates in Italy (1.8%) or Finland (2.0%); average in Poland (4.0%) or Hungary (4.4%); high in Germany (4.9%), France (5.2%), or Bulgaria (7.1%); to very high in Turkey (15.7%). The Polish ticagrelor benefit “phenomenon” in PLATO is not related to mortality since there were numerically more ticagrelor deaths, but most likely was because of questionable massive MI adjudication exclusively in the clopidogrel arm,14,15 which should be explored further. In contrast, deaths reporting from Belgium, Brazil, Denmark, Germany, India, Netherlands, and Turkey are concerning and should be verified. Unfortunately, we were unable to retrieve data from 2 high volume German centers in Wuppertal (281 patients with 20 deaths), and Dortmund (158/7), but authorities may consider reviewing this issue later. In fact, the single center Helios in Wuppertal (Germany) contributed more deaths than Australia, Austria, Belgium, and Finland combined. Other missing information arose in the dataset from Malaysia. In short, a high-

| Country* | Patients enrolled | Deaths; Clopidogrel/ Ticagrelor; (%)† |
|----------|------------------|-------------------------------------|
| Argentina | 410              | 40; 21/19; (9.76)                    |
| Australia | 83               | 3; 1/2; (3.61)                       |
| Austria   | 143              | 5; 3/2; (3.50)                       |
| Belgium   | 170              | 8; 7/1; (4.71)                       |
| Brazil    | 590              | 62; 41/21; (10.51)                   |
| Bulgaria  | 451              | 32; 18/14; (7.10)                    |
| Canada    | 401              | 12; 5/7; (2.99)                      |
| China     | 416              | 21; 12/9; (5.05)                     |
| Czech Republic | 1021 | 41; 22/19; (4.02)                   |
| Denmark   | 382              | 15; 10/5; (3.93)                     |
| Finland   | 154              | 3; 3/0; (1.95)                       |
| France    | 422              | 22; 13/9; (5.21)                     |
| Georgia   | 519              | 19; 7/12; (3.66)                     |
| Germany   | 1156             | 57; 27/30; (4.93)                    |
| Greece    | 90               | 4; 3/1; (4.44)                       |
| Hungary   | 1267             | 56; 36/20; (4.42)                    |
| India     | 575              | 52; 31/21; (9.04)                    |
| Indonesia | 62               | 14; 8/6; (22.58)                     |
| Israel    | 636              | 21; 12/9; (3.30)                     |
| Italy     | 625              | 11; 8/3 (1.76)                       |
| Malaysia  | 56               | 8; 6/2 (14.29)                       |
| Mexico    | 137              | 12; 6/6 (8.76)                       |
| Netherlands | 913          | 22; 17/5 (2.41)                     |
| Norway    | 159              | 5; 1/4 (3.14)                        |
| Philippines | 78           | 16; 10/6 (23.66)                    |
| Poland    | 2666             | 104; 51/53; (3.90)                   |
| Portugal  | 152              | 8; 3/5 (5.26)                        |
| Romania   | 397              | 22; 14/8 (5.54)                      |
| Russia    | 678              | 48; 19/29; (7.08)                    |
| South Korea | 120          | 4; 3/1 (3.33)                        |
| Singapore | 64               | 3; 3/0; (4.69)                       |
| Slovakia  | 336              | 20; 11/9; (5.95)                     |
| South Africa | 149           | 17; 8/9; (11.41)                    |
| Spain     | 314              | 13; 9/4 (4.14)                       |
| Sweden    | 347              | 12; 6/6 (3.46)                       |
| Switzerland | 211           | 8; 5/3 (3.79)                       |
| Taiwan    | 92               | 8; 2/6 (8.70)                        |
| Thailand  | 152              | 32; 19/13 (21.05)                    |
| Turkey    | 51               | 8; 6/2 (15.69)                       |
| United Kingdom | 281   | 14; 9/5 (4.98)                      |
| Ukraine   | 169              | 13; 8/5 (7.69)                       |
| USA       | 1413             | 53; 24/29 (3.75)                     |

*No deaths reported among 16 patients enrolled at a single site in Hong Kong.
†C – clopidogrel; T – ticagrelor; % - overall death rate combined for both drugs.
enrolling PLATO site operating in the urban, but remote community hospital setting moved to a new location in 2011, with trial archives entirely missing. Study materials were returned to sponsor. The NDA records indicate 4 deaths (3 on clopidogrel and 1 on ticagrelor) from that site. However, the principal investigator and study nurse repeatedly recalled no follow-up deaths recollection among enrolled patients in PLATO. These data are unconfirmed, but worth mentioning for further exploring.

Our verification efforts revealed that aside from unreported, or wrongly tabulated extra fatalities, which were not common, the mismatch in the death causes may be a major concern if confirmed in the rest of PLATO patients. In short, several clopidogrel patients were reported in the NDA as “dead” on the exact same day when in reality they experienced a non-fatal event. Such inaccuracy may have led to enhanced overall “vascular mortality reduction” claim, and to an exaggerated ticagrelor “early survival benefit” over clopidogrel so desperately needed to convince interventional cardiologists to switch for ticagrelor. Lately, the ISAR REACT 5, a large randomized trial failed to confirm a ticagrelor benefit in ACS patients when compared with prasugrel16 so as the POPularAGE...

Table 4. Mismatches between site- and NDA-reported death dates in PLATO.

| Country/PLATO ID# | Arm       | Death date (site) | Death date (NDA) | Cause of death | Comment                                           |
|-------------------|-----------|-------------------|------------------|----------------|--------------------------------------------------|
| Norway            | 34xxxxxx  | Ticagrelor        | 23Dec2008        | Jan 21, 2009   | Vascular 28-d delayed death reported at the day of last follow-up |
| Hungary           | 26xxxxxx  | Clopidogrel       | 03Mar2008        | Feb 23, 2008   | Nonvascular 10-d earlier death, misreported as vascular and sudden |
| Poland            | 36xxxxxx  | Unknown           | 31Aug2007        | No report      | Vascular Female patient (PESEL #5609xxxxxxxxxx) not in the NDA list |
| South Korea       | 40xxxxxx  | Unknown           | 02Jun2008        | No report      | Vascular Patient “YSY”, enrolled May 30, 2008, experience sudden death due to cardiac arrest, not in the NDA list |

Table 5. Misreported causes of deaths in PLATO.

| Country/PLATO ID# | Arm       | Death cause (site) | Death cause (NDA) |
|-------------------|-----------|--------------------|-------------------|
| Canada            |           |                    |                   |
| 16xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| 16xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| 16xxxxxx          | Ticagrelor| Vascular           | Nonvascular       |
| Mexico            |           |                    |                   |
| 32xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| Hungary           |           |                    |                   |
| 26xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| 26xxxxxx          | Ticagrelor| Vascular           | Unknown           |
| 26xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| 26xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |
| 26xxxxxx          | Clopidogrel| Nonvascular        | Vascular          |

American Journal of Therapeutics (2020) 27(6) www.americantherapeutics.com
study against clopidogrel in the elderly. Moreover, comprehensive data from the Swedish SWEDEHEART Registry analyzed over 14,000 elderly patients, and revealed 17% excess death risk (hazard ratio = 1.17; 95% confidence interval, 1.03–1.32) after ticagrelor when compared with clopidogrel.18

Another challenge in PLATO was the mismatch of death causes whereby “vascular” deaths were over-reported for clopidogrel, whereas underreported for ticagrelor. In fact, such a pattern was anticipated since officially published clopidogrel vascular deaths over total deaths were very high (89%) in PLATO,6 compared with 81% in ISAR-5; 76% in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel; 64% in Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin, and 52% in POPularAGE. Interestingly, there were no bleeding deaths after clopidogrel in POPularAGE,17 which were counted as “vascular” in PLATO. Moreover, in support of overall evidence, the recent ESC 2020 Guidelines

Table 6. Misreported deaths codes in PLATO.

| Country/PLATO ID# | Arm     | Death cause (site) | Death cause (NDA) | Audited cause of death |
|-------------------|---------|--------------------|-------------------|------------------------|
| Canada            | 16xxxxx | Clopidogrel        | 12-09             | 11-10                  |
|                   |         |                    |                   | Failure to thrive (not eating, drinking) in nursing home |
|                   | 16xxxxx | Clopidogrel        | 12-03             | 11-05                  |
|                   |         |                    |                   | Lung cancer, never on drug |
|                   | 16xxxxx | Ticagrelor         | 11-01             | 12-01                  |
|                   |         |                    |                   | Cardio-respiratory arrest, sudden death |
| Norway            | 34xxxxx | Ticagrelor         | 11-01             | 11-02                  |
|                   |         |                    |                   | Sudden death |
|                   | 34xxxxx | Clopidogrel        | 11-10             | 11-11                  |
|                   |         |                    |                   | Heart failure, but no drug discontinuation as reported |
| Mexico            | 32xxxxx | Clopidogrel        | 12-01             | 11-02                  |
|                   |         |                    |                   | Respiratory failure, intubation, ventilator, definite pulmonary death |
|                   | 32xxxxx | Ticagrelor         | 11-01             | 11-10                  |
|                   |         |                    |                   | Sudden death, no heart failure |
| Hungary           | 26xxxxx | Clopidogrel        | 12-01             | 11-07                  |
|                   |         |                    |                   | Respiratory failure, cancer death |
|                   | 26xxxxx | Ticagrelor         | 11-05             | 97                     |
|                   |         |                    |                   | Stroke |
|                   | 26xxxxx | Clopidogrel        | 12-07             | 11-10                  |
|                   |         |                    |                   | Renal failure |
|                   | 26xxxxx | Ticagrelor         | 11-01             | 11-10                  |
|                   |         |                    |                   | Sudden death, tamponade, autopsy confirmed |
|                   | 26xxxxx | Clopidogrel        | 11-02             | 11-01                  |
|                   |         |                    |                   | Myocardial infarction (MI) after possible stent thrombosis |
|                   | 26xxxxx | Clopidogrel        | 12-01             | 12-99                  |
|                   |         |                    |                   | Hypotension, neurological damage due to hypoxia |
|                   | 26xxxxx | Clopidogrel        | 12-01             | 11-01                  |
|                   |         |                    |                   | Respiratory failure |
|                   | 26xxxxx | Ticagrelor         | 11-01             | 11-02                  |
|                   |         |                    |                   | Sudden death |
|                   | 26xxxxx | Clopidogrel        | 12-09             | 11-10                  |
|                   |         |                    |                   | Multiorgan failure (MOF) |
|                   | 26xxxxx | Clopidogrel        | 11-02             | 11-01                  |
|                   |         |                    |                   | MI |
| Poland            | 36xxxxx | Ticagrelor         | 11-03             | 11-99                  |
|                   |         |                    |                   | Unstable angina, not unclear or “other” |
| South Korea       | 40xxxxx | Clopidogrel        | 11-02             | 11-01                  |
|                   |         |                    |                   | Documented MI, no sudden death |

For the cause of death main codes: “11” – vascular; “12” – non vascular; “97” – unknown; Vascular subcodes: “1” = sudden death; “2” = myocardial infarction; “3” = unstable angina; “4” = other coronary artery disease; “5” = stroke; “6” = arterial embolism; “7” = pulmonary embolism; “8” = ruptured aortic aneurysm; “9” = aortic dissection; “10” = heart failure; “11” = cardiac arrhythmia; “12” = death from bleeding (not trauma); “13” = endocarditis; “14” = valvular disease; “99” = other. Non-vascular codes: “1” = respiratory failure; “2” = pneumonia; “3” = cancer; “4” = trauma; “5” = suicide; “6” = liver failure; “7” = renal failure; “8” = sepsis; “9” = multiorgan failure; “99” = other.
downgraded ticagrelor and recommend prasugrel in Non ST-elevated-ACS patients undergoing coronary interventions.19

The intriguing subset of late PLATO deaths (5 clopidogrel and 2 ticagrelor) occurred in nursing homes. These deaths are usually not witnessed, with no autopsy performed. The patients were very sick with an array of comorbid diagnoses such as diabetes mellitus, hypertension, chronic obstructive pulmonary disease, anemia, arthritis, hip replacement, constipation, and cancer. Among cardiovascular diseases, heart failure, and arrhythmias are most common. Such patients usually die calmly refusing food and water, with a true cause of death as “failure to thrive.” However, 4 of 5 of nursing home clopidogrel deaths were counted as “vascular” and, despite obvious cause as “cardiac arrest,” no ticagrelor patients were reported as dead from vascular causes. The late nursing home deaths probably represent the “grey zone” for death counts in long-term trials.

It is also unclear whether patient-level paper records were available and actively used by PLATO adjudicators, or the decision on death cause was done based exclusively on the changed electronic Clinical Research Forms yielded from the already mismatched NDA dataset. Because the FDA reviewers definitely had no access to PLATO paper records, and used the .pdf files of electronic Clinical Research Form’s, most likely trial adjudicators were in the similar situation, and were unable to determine misreporting discrepancies. Finally, PLATO investigators published over 60 secondary papers explaining and promoting the benefits of ticagrelor in a variety of trial subpopulations linked to trial outcomes reflected in the NDA dataset. Importantly, the mismatches in cardiovascular origin and precise timing of PLATO deaths are now challenging the scientific validity of such scientific reports. The insight from the present study would have an impact on other pivotal trials. The presented findings implicitly mean that some of the contemporary medical progress based on results from large-scale clinical trials may have methodological and interpretation flaws. Obviously, the current analysis could preclude any more direct involvement of the sponsor to control data flow in such indication-seeking studies. It is currently unclear how the, index findings will affect overall PLATO trial results. Fortunately, the entire PLATO database is available in the cloud storage for ongoing investigation which is underway. We are unaware of any other such practices described in the paper concerning other antiplatelet drugs trials, although few things truly matter now. First, the Freedom of Information Act allows to publicly access the very intimate trial data to avoid future inaccuracies or mismatches in reporting. Further research could focus on the role of FDA in PLATO controversy including repeated sabotaged investigations of the Task Force, and woeful failures of site inspections in Hungary. The Task Force will further analyze patterns of cancer and sepsis deaths reporting, and comparison of sponsor versus third party Clinical Research Organization PLATO fatalities.

Limitations

There are obvious limitations to our report worth mentioning. We were able to retrieve and verify data
from only 861 patients, with 52 deaths. So, most PLATO fatalities are still unverified and current numbers may be not high enough to be absolutely compelling to precisely assess the magnitude of the problem. A positive impact is that more PLATO investigators are approaching us to share the death records from their sites, and we expect much larger sample size of PLATO deaths verification in the future. Also, the exact mechanisms of obtaining deaths reports differs among sites, and we assume that the investigators state correctly site-reported outcomes. However, because of the objective dichotomous nature of fatal events (events are clearly yes or no), we are sure that these events were the most appropriate ones to choose for such selective analysis. Although it is impossible to judge at this point what was the real background and the magnitude of the “mismatches” we observed, it is worth disclosing for stimulating a scientific discussion to clarify these uncertainties. It is unclear how the official adjudication applied to the various data sources. For instance, whether the data deposited into the high-level government database adjudicated events or just recorded them? And furthermore, whether it was a different level or degree of adjudication potentially anticipating such discrepancies. That is the entire task of, for example, independent Clinical Endpoint Committees or independent Clinical Adjudication Committees: to verify or to discard proposed endpoint assessments by the principal investigators from the local site. Even if this principle is more prevalent in softer endpoints such as “heart failure” or “myocardial infarctions,” this partly also applies for causes of death. It is also entirely unclear whether other outcomes, especially myocardial infarctions, cancers, infections, and bleeding were correctly reported. It is quite possible that some site records were inaccurate, but we attempted to use at least 2 independent sources to verify local evidence. The differences in record keeping quality heavily depends on participating countries, with the top scores belonging to Mexico and Canada. Since all PLATO events are kept in the cloud-based Medidata Rave electronic data capture system, securing the database content, analyses of changes or/and repeated entries, identifying potential interference origin, and assessing the full magnitude of the problem are warranted.

ACKNOWLEDGMENTS

The paper was prepared by V.S. et al of the Task Force in their personal capacity. The methodology, results, and conclusions drawn in the article are the authors’ own and do not reflect the views of BuzzFeed, Inc., or BuzzFeed News. The authors acknowledge Professor Daniel Hanley, MD (Director, Brain Injury Outcomes) for resistance with repeated attempts to remove Dr. Serebruany from Johns Hopkins faculty appointment, and Professor Eric Topol MD, the outstanding example of brightness for encouragement to seek the truth in clinical trials. Our true appreciation to clinical and statistical FDA reviewers on ticagrelor New Drug Application 22–433 for their integrity a courage with the “no approval” recommendation. At the time of NDA 22–433 review, the senior author of this paper was a Medical Team Leader for the FDA cardio-renal division. Special thanks to Thomas Sullivan from Rockpointe Corporation (Columbia, MD, USA) for help with regulatory and legal issues, and AstraZeneca former medical science liaisons Drs. David Booze and Paul Skiba for support during early ticagrelor development. For help in retrieving PLATO medical records, clinical notes, and gaining access to National Vital Registers our deep appreciation to site personnel, research coordinators, and study nurses. Special thanks for several bright US scientists who were forced to stop ticagrelor research because of sponsor threats. Our deep sympathy for several active Task Force members from Europe and Asia who helped tremendously, but decided not to disclose their names and affiliations for the index paper. The authors acknowledge professional advice, ongoing support, and close active case monitoring from the FBI Health Care Fraud Squad (Northern Virginia Field Office, Manassas, VA), especially Special Agent Dr. M.M.P. and Supervisory Special Agent J.A.T.

CONCLUSION

Details of some deaths such as causes, precise timing and actual event occurrences were inaccurately reported in PLATO favoring ticagrelor. The extent of mortality mismatch is unclear, and could challenge the entire trial validity if confirmed in the overall full dataset. Because all PLATO events are kept in the Medidata Rave electronic capture system, securing the database content, analyses of changes or/and repeated entries, identifying potential interference origin, and assessing the full magnitude of the problem are warranted.

REFERENCES

1. The FDA ticagrelor review of complete response. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022433Orig1s000MedR.pdf. Accessed June 15, 2020.
2. Serebruany VL, Fortmann S, Cherepanov V, et al. Mortality after oral platelet P2Y12 inhibitors in the food and drug administration adverse event reporting system. *Am J Med.* 2017;130:e245–e246.

3. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J.* 2019;40:87–165.

4. Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelines for the use of antiplatelet therapy. *JACC.* 2018;68:1082–1115.

5. Levine GN, Bates ER, Bittle JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. *JACC.* 2016;68:1082–1115.

6. Wallentin L, Becker RC, Budaj, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. *N Engl J Med.* 2009;361:1045–1057.

7. Mahaffey KW, Wojdyla DM, Carroll K, et al. for PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. *Circulation.* 2011;124:544–554.

8. Serebruany VL. Paradoxical excess mortality in the PLATO trial should be independently verified. *Thromb Haemost.* 2011;105:752–759.

9. DiNicolantonio JJ, Tomek A. Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel. *Int J Cardiol.* 2013;169:145–146.

10. Goto S, Huang CH, Park SJ, et al. Ticagrelor vs. Clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome - randomized, double-blind, phase III PHILO study. *Circ J.* 2015;79:2452–2460.

11. Serebruany VL, Tomek A, Pya Y, et al. Inferiority of ticagrelor in the PHILO trial: play of chance in East Asians or nightmare confirmation of PLATO-USA? *Int J Cardiol.* 2016;215:372–376.

12. Serebruany VL. Ticagrelor shift from PLATO to PEGASUS: vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events. *Int J Cardiol.* 2015;201:508–512.

13. Marciniak TA, Cherepanov V, Golukhova E, et al. Drug discontinuation and follow-up rates in oral antithrombotic trials. *JAMA Intern Med.* 2016;176:257–259.

14. Serebruany VL, Atar D. Central adjudication of myocardial infarction in outcome-driven clinical trials—common patterns in TRITON, RECORD, and PLATO? *Thromb Haemost.* 2012;108:412–414.

15. Verheugt F. Outcomes of positive randomised controlled clinical trials: double-blind or double vision? *Thromb Haemost.* 2012;108:410–411.

16. Schüpke S, Neumann FJ, Menichelli M, et al. For ISAR-REACT 5 trial investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. *N Engl J Med.* 2019;381:1524–1534.

17. Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 Years or older with non-ST-elevation acute coronary syndrome (POPularAGE): the randomized, open-label, non-inferiority trial. *Lancet.* 2020;395:1374–1381.

18. Szummer K, Montez-Rath ME, Alfredsson J, et al. Comparison between ticagrelor and clopidogrel in elderly patients with an acute coronary syndrome: insights from the SWEDHEART registry. *Circulation.* 2020 Available at: https://doi.org/10.1161/CIRCULATIONAHA.120.050645. [Epub ahead of print].

19. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J.* 2020;41:1–79.